Pulmonary Fibrosis News and Research

RSS

Could drinking tea help manage COVID-19?

Researchers summarized the content of active ingredients in different types of tea, the second most consumed beverage in the world. They also explored the possibility of using tea extracts for coronavirus disease 2019 (COVID-19) prevention and treatment.

17 Jan 2023

Understanding the molecular basis of how THC cannabinoid inhibits an important human enzyme

In various European countries and North America, medical cannabis or medicines based on cannabinoids are authorized for therapeutic purposes.

9 Jan 2023

Comprehensive lung cell atlas offers insights into an unexpected immune niche in the airways

The most comprehensive lung cell atlas to date, from the Wellcome Sanger Institute and collaborators, has revealed 11 new lung cell types and offers detailed insight into an immune process involved in fighting lung infections.

21 Dec 2022

No benefit of low dose apixaban following acute COVID-19

The HEAL-COVID trial compared the efficacy of Apixaban to standard care in adults who have recently recovered from severe COVID-19.

14 Dec 2022

What is the prevalence of pulmonary tissue injury among hospitalized COVID-19 patients?

Researchers identified risk factors for and the prevalence of persistent pulmonary tissue alterations among hospitalized coronavirus disease 2019 (COVID-19) patients.

7 Dec 2022

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Researchers evaluated compositional and structural pulmonary alterations in PASC tissues.

5 Dec 2022

Collaborative work unravels hidden molecular secrets of age-related diseases

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, and the University of Copenhagen announced today the release of the first batch of results from the collaborative work directed to perform multi-omics-based analyses in the context of age-related diseases using an AI-driven target and drug discovery pipeline.

2 Dec 2022

Analysis reveals highest number of pneumonia deaths in the UK

More people die from pneumonia in the UK than anywhere else in Europe, according to new analysis by leading lung charity, Asthma + Lung UK. Now, the charity is raising awareness of the signs and symptoms of pneumonia, and urging people who are eligible, such as those with severe asthma, pulmonary fibrosis and COPD, to get their one-off pneumonia vaccine.

10 Nov 2022

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

A new review discussed the applications of single-cell ribonucleic acid sequencing (scRNA-seq) in understanding autoimmune disorders.

17 Oct 2022

Favorable survival outcomes among COVID-19 lung transplant recipients

The survival rate of lung transplant recipients with COVID-19 respiratory failure was not significantly different than other patients.

16 Oct 2022

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).

13 Oct 2022

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

In a new study, researchers identified distinguishing immune features of coronavirus disease 2019 (COVID-19) in patients with late-resolving pulmonary fibrosis (LR COVID-PF) and early-resolving (ER COVID-PF).

4 Oct 2022

ASU scientists discover an unusual RNA biogenesis pathway

For the very first time, a study led by Julian Chen and his group in Arizona State University's School of Molecular Sciences and the Biodesign Institute's Center for the Mechanism of Evolution, has discovered an unprecedented pathway producing telomerase RNA from a protein-coding messenger RNA (mRNA).

3 Oct 2022

New screening tool accurately identifies patients at high risk of idiopathic pulmonary fibrosis

A new screening tool for electronic medical records accurately identifies patients who are at high risk of having or developing progressive scarring of the lungs, a condition called idiopathic pulmonary fibrosis, according to investigators from Weill Cornell Medicine, NewYork-Presbyterian, the University of Chicago, Brigham and Women's Hospital and Mayo Clinic.

29 Sep 2022

LncDACH1 may be a potential therapeutic target for pulmonary fibrosis

This new article publication from Acta Pharmaceutica Sinica B, discusses how LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation.

26 Sep 2022

Study using circulating spike protein and macrophage dysregulation liquid biomarkers reveals heterogeneity in PASC

In a new study, researchers designed a liquid biomarker panel consisting of macrophage and monocyte-related soluble factors and circulating spike proteins to understand profiles of immune dysregulation in patients with post-acute sequelae of COVID-19.

22 Sep 2022

Pulmonary Fibrosis News and Research

Could drinking tea help manage COVID-19?

Understanding the molecular basis of how THC cannabinoid inhibits an important human enzyme

Comprehensive lung cell atlas offers insights into an unexpected immune niche in the airways

No benefit of low dose apixaban following acute COVID-19

What is the prevalence of pulmonary tissue injury among hospitalized COVID-19 patients?

Study provides understanding of SARS-CoV-2 pulmonary infection long-term effects at the microanatomical, cellular, and molecular level

Collaborative work unravels hidden molecular secrets of age-related diseases

Analysis reveals highest number of pneumonia deaths in the UK

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Favorable survival outcomes among COVID-19 lung transplant recipients

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Multiomic comparison shows a reduction in circulating monocytes correlated with persistent post-COVID-19 pulmonary fibrosis

ASU scientists discover an unusual RNA biogenesis pathway

New screening tool accurately identifies patients at high risk of idiopathic pulmonary fibrosis

LncDACH1 may be a potential therapeutic target for pulmonary fibrosis

Study using circulating spike protein and macrophage dysregulation liquid biomarkers reveals heterogeneity in PASC

New white paper outlines the issues surrounding delays in diagnosing interstitial lung diseases

Vitamin D mediates crosstalk between COVID-19 and osteoporosis

CD98 identified as a key mediator of pro-fibrotic and acute inflammatory responses in the lung

Genetic variant associated with Alzheimer's disease plays a role in protecting against glaucoma

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News